SSRI Antidepressants: Pharmacology Made Easy & Clinically Relevant
SSRI antidepressants have been well-established and have a good safety profile compared to older antidepressants. Given their extensive use in clinical practice, this is a crucial drug class to be familiar with. Learn what is relevant & master the why.
To view this video, please enable marketing cookies from Cookie Preferences in the footer.
In this This Is Why pharmacology review, Dr. Busti walks through the Selective Serotonin Reuptake Inhibitors (SSRIs)—how they became first-line for major depressive disorder and a wide range of anxiety-related disorders, and where their real-world pitfalls live.
We compare the core agents—citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline—covering indications, mechanism, and clinical nuances that matter at the bedside. You’ll learn how dose, half-life, metabolism, and side-effect patterns influence patient-specific choices, and what to monitor for safety and success.
This episode includes practical guidance on:
- Managing sexual dysfunction, QT risk, and SIADH
- Recognizing CYP2D6 interactions
- Understanding fluoxetine’s long half-life
- Applying MAOI washout rules to avoid serotonin syndrome
- Starting low and titrating slow for anxiety
If you want to go beyond memorization and understand the why behind the what, this episode connects the science, safety, and strategy of SSRI use.
Chapters:
00:00 Introduction to SSRIs: Selective Serotonin Reuptake Inhibitors
00:23 History & Development: From MAOIs and TCAs to Modern SSRIs
00:56 SSRIs First-Line Use in MDD & Anxiety: Why SSRIs Became the Standard of Care
02:24 SSRI Drug Lineup Overview: Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram
03:19 Indications Beyond Depression: GAD, Panic Disorder, OCD, PTSD, PMDD & More
05:04 Mechanism of Action: Serotonin Transporter Blockade & CNS Pathways
09:04 Clinical Pharmacology: Receptor Activity, Half-Life, Active Metabolites & CYP Pathways
13:28 SSRI Targeted Neurotransmitter
21:48 SSRI Metabolic Pathways
23:40 Side Effects: GI, Sexual Dysfunction, Insomnia, Activation, Hyponatremia
24:32 Monitoring and Counseling Checklist for SSRI Antidepressants
#SSRI #SSRIantidepressants #pharmacology #PsychiatryPharmacology #medicaleducation
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
